Evidence map›Paper›PMID 42334259›Full record

ArticleEpilepsia2026

Gamma suppression correlates with thalamic stimulation therapeutic response in intractable epilepsy.

Zachary T Sanger, Xinbing Zhang, Thomas Lisko, Hafsa Farooqi, Steffen Ventz, Sandipan Pati, Thomas R Henry, David P Darrow, Michael C Park, Theoden I Netoff and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zachary T SangerDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-2144-1895
Xinbing ZhangDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0009-0002-8494-7180
Thomas LiskoDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
Hafsa FarooqiDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
Steffen VentzSchool of Public Health Division of Biostatistics & Health Data Science, University of Minnesota, Minneapolis, Minnesota, USA.
Sandipan PatiDepartment of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.
Thomas R HenryDepartment of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.
David P DarrowDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-9335-0584
Michael C ParkDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
Theoden I NetoffDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
Robert A McGovernDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.

Funding

Patient Specific Parameter Optimization of Thalamic Stimulation for Treatment of EpilepsyU01NS124616 · NINDS · UNIVERSITY OF MINNESOTA · PI Robert A McGovern, THEODEN I NETOFF · 2022 to 2026
$2.6M
NINDS NIH HHS U01 NS124616NINDS NIH HHS U01NS124616
6 · The paper itself

Abstract

objectiveIn patients with drug-resistant epilepsy who undergo anterior nucleus of the thalamus (ANT) deep brain stimulation (DBS), efficacy is assessed months after therapy initiation and clinicians have no guidance when choosing stimulation parameters due to the lack of real-time biomarkers. Here, we identified acute and chronic suppression of slow gamma local field potential (LFP) oscillations (SGOs) (20-50 Hz) in the ANT as a novel electrophysiological biomarker correlated with therapeutic response.

methodsParticipants enrolled in an ongoing prospective ANT-DBS parameter optimization trial (N = 11) were analyzed retrospectively for the effects of stimulation on ANT LFPs. One-minute baseline and stimulation ANT LFPs were captured across follow-up visits using a Medtronic Percept, testing different stimulation settings around the Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy (SANTE) trial clinical setting (145 Hz, 90 μs) in the clinic. Aperiodic component detrended ANT LFP power spectral density responses during stimulation were compared against each baseline responses. Participants kept a seizure diary, where responders were those who achieved greater than a 50% seizure frequency reduction compared to their pre-DBS seizure frequency.

resultsIn the seven participants exhibiting SGOs, six were responders. Progressive suppression ("gamma fade") of SGOs under chronic stimulation correlated with long-term seizure reduction in five of six responders. Acute stimulation in-clinic with multiple settings suppressed SGOs in four of five responders, challenging fixed-programming paradigms, with only one responder using the clinical gold standard parameters at the last follow-up visit. SIGNIFICANCE: These findings establish SGO suppression as a potential multiscale biomarker for responder identification, parameter titration, and therapeutic tracking for precise, biomarker-guided intervention.

Indexed as

Anterior Thalamic NucleiDeep Brain StimulationDrug Resistant EpilepsyGamma RhythmAdultElectroencephalographyFemaleHumansLocal Field Potential MeasurementMaleRetrospective StudiesThalamusTreatment OutcomeYoung AdultANT‐DBSgammaneurmodulationseizuresslow gamma

Identifiers

PMID42334259
PMCPMC13440434

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.